Search companies on Owler
Advanced Search
Latest news
Newsfeed
My followed companies
Followed Companies

Black Diamond Therapeutics

Black Diamond Therapeutics develops and commercializes immunotherapies and precision medicines for the treatment of cancer. Read more

9 Followers on Owler
9 Followers on Owler
9 Followers on Owler
9 Followers on Owler

Black Diamond Therapeutics

Black Diamond Therapeutics develops and commercializes immunotherapies and precision medicines for the treatment of cancer. Read more

David M. Epstein's photo - President & CEO of Black Diamond Therapeutics

President & CEO

David M. Epstein

CEO Approval Rating

89/100

Founded:

2016

Status:

PublicIndependent CompanyNASDAQBDTX

SIC Code:

2836 NAICS listing »

Website:

Annual Revenue
Employees
Sector
Biotechnology
Headquarters

BLACK DIAMOND THERAPEUTICS TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

The top 10 competitors in Black Diamond Therapeutics' competitive set are NexImmune, Apexigen, FORMA Therapeutics, Aileron Therapeutics, Oncorus, OncBioMune, Xenetic, Jounce, Advanced Proteome Therapeutics, Achaogen. Together they have raised over 3.6B between their estimated 68.3K employees. Black Diamond Therapeutics has 58 employees and is ranked 8th among it's top 10 competitors. The top 10 competitors average 3,301.

NexImmune is a top competitor of Black Diamond Therapeutics. NexImmune is a Public company that was founded in 2011 in Gaithersburg, Maryland. NexImmune operates in the Biotechnology industry. Compared to Black Diamond Therapeutics, NexImmune has 13 fewer employees.

Apexigen is seen as one of Black Diamond Therapeutics's biggest rivals. Apexigen was founded in 2010, and is headquartered in San Carlos, California. Apexigen is in the Biotechnology industry. Apexigen generates $7.1M more revenue vs. Black Diamond Therapeutics.

FORMA Therapeutics is seen as one of Black Diamond Therapeutics's top competitors. FORMA Therapeutics was founded in Watertown, Massachusetts} in 2007. FORMA Therapeutics competes in the Pharmaceuticals industry. Compared to Black Diamond Therapeutics, FORMA Therapeutics generates $100.6M more revenue.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Aileron Therapeutics a competitor of Black Diamond Therapeutics?

I don't know

Trending News for Black Diamond Therapeutics and Black Diamond Therapeutics's Competitors

Today 2:11 PM

Benzinga

Apellis Pharmaceuticals To Stop Testing APL-9 In Severe COVID-19 Patients

Following an interim review of mortality data by an independent data monitoring committee (DMC), Apel... See more »

March 3, 2021

FinanzNachrichten

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Life Sciences Conference

FRAMINGHAM, MA / ACCESSWIRE / March 3, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or t... See more »

March 4, 2021

Endpoints News

Apellis joins the growing number of biopharmas scrapping a failed Covid-19 program after an early flop

The global pandemic set off a frenzy of R&D activity as biotechs around the world scrambled to see if... See more »

Black Diamond Therapeutics Quarterly and Annual Revenue

Coming soon for Black Diamond Therapeutics!

Annual Revenue

Black Diamond Therapeutics Acquisitions

No recent acquisitions found related to Black Diamond Therapeutics

Black Diamond Therapeutics Funding History

$12.1M$37.1M$207.1M$408.2M

Since Black Diamond Therapeutics was founded in 2016, it has participated in 6 rounds of funding. In total Black Diamond Therapeutics has raised $408.2M. Black Diamond Therapeutics' last funding round was on Jan 2020 for a total of $201.1M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

IPO
Jan 2020
$201.1M

Series C
Nov 2019
$85M
Series B
Jan 2019
$85M
Series A
Dec 2018
$20M
Equity
Aug 2018
$5M
-

Total Funding: $408.2M

Since Black Diamond Therapeutics was founded in 2016, it has participated in 6 rounds of funding. In total Black Diamond Therapeutics has raised $408.2M. Black Diamond Therapeutics' last funding round was on Jan 2020 for a total of $201.1M

Black Diamond Therapeutics Investments

No recent investments found related to Black Diamond Therapeutics

Black Diamond Therapeutics News

January 5, 2021Benzinga

Black Diamond Therapeutics to Present at the J.P. Morgan 39th Annual Healthcare Conference

CAMBRIDGE, Mass. and NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NA... See more »
November 24, 2020Benzinga

Black Diamond Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

CAMBRIDGE, Mass. and NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NA... See more »
November 20, 2020MarketScreener

Black Diamond Therapeutics Provides Update on GBM Program and Presents Pre-Clinical Data at the 2020 SNO Annual Meeting

(marketscreener.com) BDTX-1535 nominated as development candidate with IND-enabling studies underwayP... See more »
November 20, 2020Seeking Alpha

Black Diamond nominates development candidate for glioblastoma program

See more »
November 11, 2020MarketScreener

Black Diamond Therapeutics to Present at the Jefferies 2020 Virtual London Healthcare Conference

(marketscreener.com) CAMBRIDGE, Mass. and NEW YORK, Nov. 11, 2020 -- Black Diamond Therapeutics, Inc.... See more »
November 10, 2020BioSpace

Black Diamond Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Continued to enroll and dose patients in Phase 1/2 clinical trial of BDTX-189, with Phase 1 portion o... See more »
October 26, 2020MarketScreener

Black Diamond Therapeutics Presents Pre-Clinical Data on Lead Product Candidate BDTX-189 at the 32nd EORTC-NCI-AACR Virtual Symposium

(marketscreener.com) CAMBRIDGE, Mass. and NEW YORK, Oct. 26, 2020 -- Black Diamond Therapeutics, Inc.... See more »

Black Diamond Therapeutics Press Releases

January 9, 2019StreetInsider

Black Diamond Therapeutics Closes $85 Million Series B Financing

CAMBRIDGE, Mass. and BASEL, Switzerland, Jan. 9, 2019 /PRNewswire/ -- Black Diamond Therapeutics, Inc... See more »

Social Media

Black Diamond Therapeutics Headquarters

One Main Street 10th Floor

Cambridge, Massachusetts02142

617-252-0848

Driving Directions »

Trending Companies

Black Diamond Therapeutics Summary

ABOUT

Overview

Black Diamond Therapeutics develops and commercializes immunotherapies and precision medicines for the treatment of cancer. Black Diamond Therapeutics was founded in 2016. Black Diamond Therapeutics' headquarters is located in Cambridge, Massachusetts...

CEO

Black Diamond Therapeutics's President & CEO, David M. Epstein, currently has an approval rating of 89%. Black Diamond Therapeutics's primary competitors are NexImmune, Apexigen & FORMA Therapeutics.

Website

blackdiamondtherapeutics.com

Frequently Asked Questions about Black Diamond Therapeutics

  1. When was Black Diamond Therapeutics founded?

    Black Diamond Therapeutics was founded in 2016

  2. Who is Black Diamond Therapeutics's CEO?

    Black Diamond Therapeutics's CEO is David M. Epstein

  3. How much revenue does Black Diamond Therapeutics generate?

    Black Diamond Therapeutics generates $ < 1M in revenue

  4. How much funding does Black Diamond Therapeutics have?

    Black Diamond Therapeutics has historically raised $408.2M in funding

  1. Where is Black Diamond Therapeutics's headquarters?

    Black Diamond Therapeutics's headquarters is in Cambridge Massachusetts, USA

  2. How many employees does Black Diamond Therapeutics have?

    Black Diamond Therapeutics has 58 employees

  3. What sector does Black Diamond Therapeutics operate in?

    Black Diamond Therapeutics is in Biotechnology

  4. Who are Black Diamond Therapeutics's competitors?

    Black Diamond Therapeutics's top competitors are NexImmune, Apexigen, FORMA Therapeutics
Stay up-to-date with the latest news on Black Diamond Therapeutics

© 2021 Owler, Inc.